Skip to main content

CHICAGO (

TheStreet

) -- Welcome to TheStreet's live-blog coverage of the

American Society of Clinical Oncology

(ASCO) annual meeting. It's Monday, which means the big focus will be on how ASCO-related cancer drug stocks react once trading opens.

Here at the meeting, data presentations continue for a fourth day. Later this morning,

Neoprobe

(NEOP)

will be presenting a poster on its lymph-node mapping agent Lymphoseek. Also this morning, data from the two phase III studies of

Incyte's

(INCY) - Get Incyte Corporation Report

myelofibrosis drug ruxolitinib will be presented.

How will investors react to

YM BioSciences

(YMI)

after data on CYT387 was presented Friday?

TheStreet Recommends

Investors will be paying attention to a prostate cancer session this afternoon that will include data presentation from

Pfizer

(PFE) - Get Pfizer Inc. Report

,

Exelixis

(EXEL) - Get Exelixis, Inc. Report

,

Dendreon

(DNDN)

and

Johnson & Johnson

(JNJ) - Get Johnson & Johnson Report

.

Ariad Pharmaceuticals

(ARIA)

,

Cyclacel Pharmaceuticals

(CYCC) - Get Cyclacel Pharmaceuticals, Inc. Report

and

Pharmacyclics

(PCYC)

also take a turn on the ASCO stage today.

Follow this live blog throughout the day for continuous updates and reports from the ASCO meeting. I'll be reporting on clinical data presentations as I see and hear them, and I'll be blogging from the hallways, exhibition hall and meeting rooms, giving you a real-time perspective on all the investor-worthy buzz. With my new iPad2 and some nifty software, I'll even try to bring you photos and audio for a deeper, multimedia perspective.

I welcome your comments and questions on this live blog, too, which I'll do my best to answer and publish as time permits. You can also follow my ASCO 2010 coverage on Twitter.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here:

Adam Feuerstein

.

>To follow the writer on Twitter, go to

http://twitter.com/adamfeuerstein

.

>To submit a news tip, send an email to:

tips@thestreet.com

.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

click here

to send him an email.